3.9.2026 23:20:48 CEST | Thor Medical ASA | Major shareholdings notification
Oslo, Norway, 3 September 2026: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding
the completion of a private placement of new shares to be issued by the Company
(the "Private Placement") and a retail offering through Nordnet (the "Nordnet
Offering").
Scatec Innovation AS has agreed to lend existing and unencumbered shares in the
Company, already being traded on Euronext Oslo Børs, to Arctic Securities AS and
ABG Sundal Collier ASA (the "Managers") for the Private Placement and the
Nordnet Offering. Borrowed shares will be used for settlement towards investors
having been allocated shares in the Private Placement and the Nordnet Offering
and redelivered to Scatec Innovation AS upon registration of the share capital
increase pertaining to the Private Placement and the Nordnet Offering.
Prior to the completion of the Private Placement, Scatec Innovation AS held
82,118,280 shares in the Company, representing approx. 22.81 % of the issued
share capital and votes. Scatec Innovation AS has lent a total of 57,291,667
existing shares which will be delivered to the investors in the Private
Placement and the Nordnet Offering, other than Scatec Innovation AS.
During the term of the loan, and prior to the redelivery, Scatec Innovation AS'
shareholding in the Company will be reduced to 24,826,613, equivalent to approx.
6.90% of the issued share capital and votes. Consequently, Scatec Innovation AS
has fallen below the 20%, 15% and 10% thresholds pursuant to section 4-2 (1) and
(3) of the Norwegian Securities Trading Act.
This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act.
CONTACTS
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05
724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
www.thormedical.com - http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19051451/16898/Download%20announc
ement%20as%20PDF.pdf
://kommunikasjon.ntb.no/ir-files/17848634/19051451/16898/Download%20announc\
ement%20as%20PDF.pdf\